Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Overcoming barriers in progressive multiple sclerosis research.
First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS.
Epigenetic changes in patients with multiple sclerosis.
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
The AusD Study: A Population-based Study of the Determinants of Serum 25-Hydroxyvitamin D Concentration Across a Broad Latitude Range.
SMC Says Yes to Lemtrada(R)a- 1/4 (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple Sclerosis (RRMS)
Motor skill learning requires active central myelination.
Laquinimod - New Promising Treatment for Multiple Sclerosis
Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-beta-1b: a case report.
MHC class I-restricted myelin epitopes are cross-presented by Tip-DCs that promote determinant spreading to CD8(+) T cells.
Multiple sclerosis.
Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination.
High dose thiamine improves fatigue in multiple sclerosis.
First use of alemtuzumab in Balo's concentric sclerosis: a case report.
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Identification of Selective Inhibitors of the Potassium Channel Kv1.1-1.2((3)) by High-Throughput Virtual Screening and Automated Patch Clamp.
Severe anemia in a patient with multiple sclerosis treated with natalizumab.
Metabolic features of the cell danger response.
Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS.
Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.
Neuromyelitis optica spectrum disorder: 2-deoxy-2-[(18)f]fluoro-d-glucose positron emission tomography findings.

Pages